[{"edinetCode":"E25269","endDate":"2016\/12\/31","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":6257300.0,"sharesOwendPercent":0.3334,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":null,"cashAndCashEquivalents":null,"assets":null,"currentAssets":null,"fixedAsset":null,"tangibleFixedAssets":null,"intangibleFixedAssets":null,"investmentAndOtherAssets":null,"liabilities":null,"currentLiabilities":null,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":null,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":null,"capitalStock":null,"capital":null,"capitalSurplus":null,"accumulatedEarnings":null,"treasuryStock":null,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":null,"costOfSales":null,"grossProfit":null,"sgaExpenses":null,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":null,"nonOperatingIncome":null,"nonOperatingExpenses":null,"interestExpense":null,"ordinaryProfit":null,"extraordinaryGain":null,"extraordinaryLoss":null,"incomeBeforeTax":null,"incomeTaxes":null,"netIncome":null,"netIncomeAttributableToOwnersOfTheParentCompany":null,"comprehensiveIncome":null,"eps":null,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"asr","submitDate":"2017\/3\/31","stockCode":4579,"accountingYear":"第９期（自　平成28年１月１日　至　平成28年12月31日）","accountingYearStart":"2016\/1\/1","accountingYearEnd":"2016\/12\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":false,"edinetCode2":"E25269","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":2254,"settlementDate":"2022\/12\/31","submitterName":"ラクオリア創薬株式会社","submitterNameEnglish":"RaQualia Pharma Inc.","submitterNameKana":"ラクオリアソウヤクカブシキカイシャ","location":"名古屋市中村区名駅南一丁目２１番１９号","industory":"医薬品","corporateNumber":3180000000000.0},{"edinetCode":"E25269","endDate":"2017\/12\/31","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":60.0,"averageTemporaryStaff":7.0,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":4516260.0,"sharesOwendPercent":0.2225,"outstandingShares":null,"numberOfSubsidiary":1.0,"bps":240.0,"equityRatio":0.962,"cashAndCashEquivalents":2473916000.0,"assets":5064188000.0,"currentAssets":3322398000.0,"fixedAsset":1741790000.0,"tangibleFixedAssets":215680000.0,"intangibleFixedAssets":9955000.0,"investmentAndOtherAssets":1516154000.0,"liabilities":176237000.0,"currentLiabilities":148763000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":27474000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":4887950000.0,"capitalStock":4886607000.0,"capital":2741249000.0,"capitalSurplus":2931032000.0,"accumulatedEarnings":-785652000.0,"treasuryStock":-21000.0,"valuationAndConversionAdjustments":-15826000.0,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":null,"costOfSales":null,"grossProfit":null,"sgaExpenses":null,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":-150411000.0,"nonOperatingIncome":84665000.0,"nonOperatingExpenses":14829000.0,"interestExpense":null,"ordinaryProfit":-80575000.0,"extraordinaryGain":20926000.0,"extraordinaryLoss":199000.0,"incomeBeforeTax":-59848000.0,"incomeTaxes":-1725000.0,"netIncome":-58122000.0,"netIncomeAttributableToOwnersOfTheParentCompany":-58122000.0,"comprehensiveIncome":-100132000.0,"eps":-2.99,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":-307434000.0,"depreciationAndCashflowFromOperatingActivities":85785000.0,"cashFlowFromInvestingActivities":533800000.0,"cashFlowFromFinancialActivities":1007321000.0,"changesInCashAndCashEquivalents":1229426000.0,"列1":"asr","submitDate":"2018\/3\/30","stockCode":4579,"accountingYear":"第10期（自　平成29年１月１日　至　平成29年12月31日）","accountingYearStart":"2017\/1\/1","accountingYearEnd":"2017\/12\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E25269","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":2254,"settlementDate":"2022\/12\/31","submitterName":"ラクオリア創薬株式会社","submitterNameEnglish":"RaQualia Pharma Inc.","submitterNameKana":"ラクオリアソウヤクカブシキカイシャ","location":"名古屋市中村区名駅南一丁目２１番１９号","industory":"医薬品","corporateNumber":3180000000000.0},{"edinetCode":"E25269","endDate":"2018\/12\/31","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":63.0,"averageTemporaryStaff":5.0,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":3725272.0,"sharesOwendPercent":0.1827,"outstandingShares":null,"numberOfSubsidiary":2.0,"bps":188.57,"equityRatio":0.949,"cashAndCashEquivalents":1829540000.0,"assets":4052302000.0,"currentAssets":1962252000.0,"fixedAsset":2090049000.0,"tangibleFixedAssets":317795000.0,"intangibleFixedAssets":33985000.0,"investmentAndOtherAssets":1738267000.0,"liabilities":195214000.0,"currentLiabilities":164492000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":30722000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":3857087000.0,"capitalStock":3886476000.0,"capital":2793458000.0,"capitalSurplus":2983241000.0,"accumulatedEarnings":-1890201000.0,"treasuryStock":-21000.0,"valuationAndConversionAdjustments":-41901000.0,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":null,"costOfSales":null,"grossProfit":null,"sgaExpenses":null,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":-1075109000.0,"nonOperatingIncome":45218000.0,"nonOperatingExpenses":34960000.0,"interestExpense":null,"ordinaryProfit":-1064851000.0,"extraordinaryGain":4577000.0,"extraordinaryLoss":17919000.0,"incomeBeforeTax":-1078193000.0,"incomeTaxes":26355000.0,"netIncome":-1104548000.0,"netIncomeAttributableToOwnersOfTheParentCompany":-1104548000.0,"comprehensiveIncome":-1130624000.0,"eps":-54.23,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":-403997000.0,"depreciationAndCashflowFromOperatingActivities":125588000.0,"cashFlowFromInvestingActivities":-368057000.0,"cashFlowFromFinancialActivities":99185000.0,"changesInCashAndCashEquivalents":-644375000.0,"列1":"asr","submitDate":"2019\/3\/26","stockCode":4579,"accountingYear":"第11期（自　平成30年１月１日　至　平成30年12月31日）","accountingYearStart":"2018\/1\/1","accountingYearEnd":"2018\/12\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E25269","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":2254,"settlementDate":"2022\/12\/31","submitterName":"ラクオリア創薬株式会社","submitterNameEnglish":"RaQualia Pharma Inc.","submitterNameKana":"ラクオリアソウヤクカブシキカイシャ","location":"名古屋市中村区名駅南一丁目２１番１９号","industory":"医薬品","corporateNumber":3180000000000.0},{"edinetCode":"E25269","endDate":"2019\/3\/31","Report abbreviation_x":"q1r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.935,"cashAndCashEquivalents":1371738000.0,"assets":4025559000.0,"currentAssets":1898651000.0,"fixedAsset":2126908000.0,"tangibleFixedAssets":338597000.0,"intangibleFixedAssets":33017000.0,"investmentAndOtherAssets":1755293000.0,"liabilities":236304000.0,"currentLiabilities":211015000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":25288000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":3789255000.0,"capitalStock":3783545000.0,"capital":2793458000.0,"capitalSurplus":2983241000.0,"accumulatedEarnings":-1993133000.0,"treasuryStock":-21000.0,"valuationAndConversionAdjustments":-20051000.0,"Report abbreviation_y":"q1r","context_y":"当四半期累計期間連結期間","Sales":null,"costOfSales":null,"grossProfit":null,"sgaExpenses":null,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":-104223000.0,"nonOperatingIncome":17592000.0,"nonOperatingExpenses":8702000.0,"interestExpense":null,"ordinaryProfit":-95333000.0,"extraordinaryGain":null,"extraordinaryLoss":null,"incomeBeforeTax":-95333000.0,"incomeTaxes":7597000.0,"netIncome":-102931000.0,"netIncomeAttributableToOwnersOfTheParentCompany":-102931000.0,"comprehensiveIncome":-81081000.0,"eps":-5.05,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":-385704000.0,"depreciationAndCashflowFromOperatingActivities":34292000.0,"cashFlowFromInvestingActivities":-78832000.0,"cashFlowFromFinancialActivities":4361000.0,"changesInCashAndCashEquivalents":-457802000.0,"列1":"q1r","submitDate":"2019\/5\/14","stockCode":4579,"accountingYear":null,"accountingYearStart":"2019\/1\/1","accountingYearEnd":"2019\/12\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E25269","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":2254,"settlementDate":"2022\/12\/31","submitterName":"ラクオリア創薬株式会社","submitterNameEnglish":"RaQualia Pharma Inc.","submitterNameKana":"ラクオリアソウヤクカブシキカイシャ","location":"名古屋市中村区名駅南一丁目２１番１９号","industory":"医薬品","corporateNumber":3180000000000.0},{"edinetCode":"E25269","endDate":"2019\/6\/30","Report abbreviation_x":"q2r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":3888805.0,"sharesOwendPercent":0.1881,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.96,"cashAndCashEquivalents":1997899000.0,"assets":4095594000.0,"currentAssets":2288135000.0,"fixedAsset":1807458000.0,"tangibleFixedAssets":305248000.0,"intangibleFixedAssets":32631000.0,"investmentAndOtherAssets":1469578000.0,"liabilities":143760000.0,"currentLiabilities":115673000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":28086000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":3951834000.0,"capitalStock":3945307000.0,"capital":2085055000.0,"capitalSurplus":2274838000.0,"accumulatedEarnings":-414565000.0,"treasuryStock":-21000.0,"valuationAndConversionAdjustments":-12484000.0,"Report abbreviation_y":"q2r","context_y":"当四半期累計期間連結期間","Sales":null,"costOfSales":null,"grossProfit":null,"sgaExpenses":null,"salaryAndBenefit":84377000.0,"depreciationAndSGA":2366000.0,"RDExpenses":null,"operatingIncome":-302693000.0,"nonOperatingIncome":27590000.0,"nonOperatingExpenses":32549000.0,"interestExpense":null,"ordinaryProfit":-307651000.0,"extraordinaryGain":5727000.0,"extraordinaryLoss":null,"incomeBeforeTax":-301924000.0,"incomeTaxes":8125000.0,"netIncome":-310050000.0,"netIncomeAttributableToOwnersOfTheParentCompany":-310050000.0,"comprehensiveIncome":-280633000.0,"eps":-15.19,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":-391343000.0,"depreciationAndCashflowFromOperatingActivities":68585000.0,"cashFlowFromInvestingActivities":220909000.0,"cashFlowFromFinancialActivities":366083000.0,"changesInCashAndCashEquivalents":168358000.0,"列1":"q2r","submitDate":"2019\/8\/9","stockCode":4579,"accountingYear":null,"accountingYearStart":"2019\/1\/1","accountingYearEnd":"2019\/12\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E25269","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":2254,"settlementDate":"2022\/12\/31","submitterName":"ラクオリア創薬株式会社","submitterNameEnglish":"RaQualia Pharma Inc.","submitterNameKana":"ラクオリアソウヤクカブシキカイシャ","location":"名古屋市中村区名駅南一丁目２１番１９号","industory":"医薬品","corporateNumber":3180000000000.0},{"edinetCode":"E25269","endDate":"2019\/9\/30","Report abbreviation_x":"q3r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.956,"cashAndCashEquivalents":1859165000.0,"assets":3896735000.0,"currentAssets":2110212000.0,"fixedAsset":1786523000.0,"tangibleFixedAssets":283357000.0,"intangibleFixedAssets":33275000.0,"investmentAndOtherAssets":1469890000.0,"liabilities":153489000.0,"currentLiabilities":126862000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":26627000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":3743246000.0,"capitalStock":3734410000.0,"capital":2090500000.0,"capitalSurplus":2280283000.0,"accumulatedEarnings":-636351000.0,"treasuryStock":-21000.0,"valuationAndConversionAdjustments":-9941000.0,"Report abbreviation_y":"q3r","context_y":"当四半期累計期間連結期間","Sales":null,"costOfSales":null,"grossProfit":null,"sgaExpenses":null,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":-534037000.0,"nonOperatingIncome":40131000.0,"nonOperatingExpenses":34045000.0,"interestExpense":null,"ordinaryProfit":-527951000.0,"extraordinaryGain":5728000.0,"extraordinaryLoss":null,"incomeBeforeTax":-522223000.0,"incomeTaxes":9612000.0,"netIncome":-531836000.0,"netIncomeAttributableToOwnersOfTheParentCompany":-531836000.0,"comprehensiveIncome":-499875000.0,"eps":-25.94,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":-544334000.0,"depreciationAndCashflowFromOperatingActivities":101937000.0,"cashFlowFromInvestingActivities":226245000.0,"cashFlowFromFinancialActivities":375018000.0,"changesInCashAndCashEquivalents":29624000.0,"列1":"q3r","submitDate":"2019\/11\/8","stockCode":4579,"accountingYear":null,"accountingYearStart":"2019\/1\/1","accountingYearEnd":"2019\/12\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E25269","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":2254,"settlementDate":"2022\/12\/31","submitterName":"ラクオリア創薬株式会社","submitterNameEnglish":"RaQualia Pharma Inc.","submitterNameKana":"ラクオリアソウヤクカブシキカイシャ","location":"名古屋市中村区名駅南一丁目２１番１９号","industory":"医薬品","corporateNumber":3180000000000.0},{"edinetCode":"E25269","endDate":"2019\/12\/31","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":68.0,"averageTemporaryStaff":6.0,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":3397150.0,"sharesOwendPercent":0.1622,"outstandingShares":null,"numberOfSubsidiary":2.0,"bps":219.97,"equityRatio":0.953,"cashAndCashEquivalents":2200206000.0,"assets":4836561000.0,"currentAssets":3067147000.0,"fixedAsset":1769413000.0,"tangibleFixedAssets":248881000.0,"intangibleFixedAssets":32485000.0,"investmentAndOtherAssets":1488047000.0,"liabilities":215914000.0,"currentLiabilities":183074000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":32839000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":4620647000.0,"capitalStock":4600476000.0,"capital":2254943000.0,"capitalSurplus":2444726000.0,"accumulatedEarnings":-99172000.0,"treasuryStock":-21000.0,"valuationAndConversionAdjustments":7906000.0,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":null,"costOfSales":null,"grossProfit":null,"sgaExpenses":null,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":-15945000.0,"nonOperatingIncome":49396000.0,"nonOperatingExpenses":11867000.0,"interestExpense":null,"ordinaryProfit":21583000.0,"extraordinaryGain":5728000.0,"extraordinaryLoss":null,"incomeBeforeTax":27311000.0,"incomeTaxes":21968000.0,"netIncome":5343000.0,"netIncomeAttributableToOwnersOfTheParentCompany":5343000.0,"comprehensiveIncome":55151000.0,"eps":0.26,"dilutedEps":0.26,"dividendPerShare":null,"per":5157.69,"roe":0.001,"cashFlowFromOperatingActivities":-530848000.0,"depreciationAndCashflowFromOperatingActivities":140050000.0,"cashFlowFromInvestingActivities":216204000.0,"cashFlowFromFinancialActivities":695905000.0,"changesInCashAndCashEquivalents":370666000.0,"列1":"asr","submitDate":"2020\/3\/27","stockCode":4579,"accountingYear":"第12期（自　2019年１月１日　至　2019年12月31日）","accountingYearStart":"2019\/1\/1","accountingYearEnd":"2019\/12\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E25269","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":2254,"settlementDate":"2022\/12\/31","submitterName":"ラクオリア創薬株式会社","submitterNameEnglish":"RaQualia Pharma Inc.","submitterNameKana":"ラクオリアソウヤクカブシキカイシャ","location":"名古屋市中村区名駅南一丁目２１番１９号","industory":"医薬品","corporateNumber":3180000000000.0},{"edinetCode":"E25269","endDate":"2020\/3\/31","Report abbreviation_x":"q1r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.949,"cashAndCashEquivalents":2430352000.0,"assets":4468763000.0,"currentAssets":2828795000.0,"fixedAsset":1639967000.0,"tangibleFixedAssets":267989000.0,"intangibleFixedAssets":32897000.0,"investmentAndOtherAssets":1339081000.0,"liabilities":214167000.0,"currentLiabilities":189128000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":25038000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":4254596000.0,"capitalStock":4272654000.0,"capital":2255096000.0,"capitalSurplus":2444879000.0,"accumulatedEarnings":-427299000.0,"treasuryStock":-21000.0,"valuationAndConversionAdjustments":-30205000.0,"Report abbreviation_y":"q1r","context_y":"当四半期累計期間連結期間","Sales":null,"costOfSales":null,"grossProfit":null,"sgaExpenses":null,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":-273385000.0,"nonOperatingIncome":18136000.0,"nonOperatingExpenses":12536000.0,"interestExpense":null,"ordinaryProfit":-267785000.0,"extraordinaryGain":5518000.0,"extraordinaryLoss":null,"incomeBeforeTax":-262267000.0,"incomeTaxes":65859000.0,"netIncome":-328127000.0,"netIncomeAttributableToOwnersOfTheParentCompany":-328127000.0,"comprehensiveIncome":-366239000.0,"eps":-15.66,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":134285000.0,"depreciationAndCashflowFromOperatingActivities":24985000.0,"cashFlowFromInvestingActivities":105855000.0,"cashFlowFromFinancialActivities":-75000.0,"changesInCashAndCashEquivalents":230145000.0,"列1":"q1r","submitDate":"2020\/5\/15","stockCode":4579,"accountingYear":null,"accountingYearStart":"2020\/1\/1","accountingYearEnd":"2020\/12\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E25269","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":2254,"settlementDate":"2022\/12\/31","submitterName":"ラクオリア創薬株式会社","submitterNameEnglish":"RaQualia Pharma Inc.","submitterNameKana":"ラクオリアソウヤクカブシキカイシャ","location":"名古屋市中村区名駅南一丁目２１番１９号","industory":"医薬品","corporateNumber":3180000000000.0},{"edinetCode":"E25269","endDate":"2020\/6\/30","Report abbreviation_x":"q2r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":4455034.0,"sharesOwendPercent":0.2126,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.948,"cashAndCashEquivalents":2152853000.0,"assets":4364173000.0,"currentAssets":2633758000.0,"fixedAsset":1730414000.0,"tangibleFixedAssets":276488000.0,"intangibleFixedAssets":33342000.0,"investmentAndOtherAssets":1420583000.0,"liabilities":213070000.0,"currentLiabilities":185193000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":27877000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":4151103000.0,"capitalStock":4141320000.0,"capital":2255096000.0,"capitalSurplus":2444879000.0,"accumulatedEarnings":-558633000.0,"treasuryStock":-21000.0,"valuationAndConversionAdjustments":-2364000.0,"Report abbreviation_y":"q2r","context_y":"当四半期累計期間連結期間","Sales":null,"costOfSales":null,"grossProfit":null,"sgaExpenses":null,"salaryAndBenefit":83413000.0,"depreciationAndSGA":2127000.0,"RDExpenses":null,"operatingIncome":-403495000.0,"nonOperatingIncome":25105000.0,"nonOperatingExpenses":24261000.0,"interestExpense":null,"ordinaryProfit":-402652000.0,"extraordinaryGain":7191000.0,"extraordinaryLoss":null,"incomeBeforeTax":-395461000.0,"incomeTaxes":63999000.0,"netIncome":-459460000.0,"netIncomeAttributableToOwnersOfTheParentCompany":-459460000.0,"comprehensiveIncome":-469731000.0,"eps":-21.93,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":-35537000.0,"depreciationAndCashflowFromOperatingActivities":53781000.0,"cashFlowFromInvestingActivities":9683000.0,"cashFlowFromFinancialActivities":-260000.0,"changesInCashAndCashEquivalents":-47353000.0,"列1":"q2r","submitDate":"2020\/8\/14","stockCode":4579,"accountingYear":null,"accountingYearStart":"2020\/1\/1","accountingYearEnd":"2020\/12\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E25269","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":2254,"settlementDate":"2022\/12\/31","submitterName":"ラクオリア創薬株式会社","submitterNameEnglish":"RaQualia Pharma Inc.","submitterNameKana":"ラクオリアソウヤクカブシキカイシャ","location":"名古屋市中村区名駅南一丁目２１番１９号","industory":"医薬品","corporateNumber":3180000000000.0},{"edinetCode":"E25269","endDate":"2020\/9\/30","Report abbreviation_x":"q3r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.946,"cashAndCashEquivalents":2310051000.0,"assets":4130259000.0,"currentAssets":2764335000.0,"fixedAsset":1365924000.0,"tangibleFixedAssets":287574000.0,"intangibleFixedAssets":31409000.0,"investmentAndOtherAssets":1046940000.0,"liabilities":212677000.0,"currentLiabilities":184465000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":28211000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":3917582000.0,"capitalStock":3902128000.0,"capital":2255096000.0,"capitalSurplus":2444879000.0,"accumulatedEarnings":-797824000.0,"treasuryStock":-21000.0,"valuationAndConversionAdjustments":3306000.0,"Report abbreviation_y":"q3r","context_y":"当四半期累計期間連結期間","Sales":null,"costOfSales":null,"grossProfit":null,"sgaExpenses":null,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":-600770000.0,"nonOperatingIncome":30793000.0,"nonOperatingExpenses":45279000.0,"interestExpense":null,"ordinaryProfit":-615256000.0,"extraordinaryGain":9180000.0,"extraordinaryLoss":6127000.0,"incomeBeforeTax":-612203000.0,"incomeTaxes":86449000.0,"netIncome":-698652000.0,"netIncomeAttributableToOwnersOfTheParentCompany":-698652000.0,"comprehensiveIncome":-703252000.0,"eps":-33.35,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":-95249000.0,"depreciationAndCashflowFromOperatingActivities":86405000.0,"cashFlowFromInvestingActivities":246788000.0,"cashFlowFromFinancialActivities":-445000.0,"changesInCashAndCashEquivalents":109844000.0,"列1":"q3r","submitDate":"2020\/11\/13","stockCode":4579,"accountingYear":null,"accountingYearStart":"2020\/1\/1","accountingYearEnd":"2020\/12\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E25269","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":2254,"settlementDate":"2022\/12\/31","submitterName":"ラクオリア創薬株式会社","submitterNameEnglish":"RaQualia Pharma Inc.","submitterNameKana":"ラクオリアソウヤクカブシキカイシャ","location":"名古屋市中村区名駅南一丁目２１番１９号","industory":"医薬品","corporateNumber":3180000000000.0},{"edinetCode":"E25269","endDate":"2020\/12\/31","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":70.0,"averageTemporaryStaff":5.0,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":5236738.0,"sharesOwendPercent":0.2499,"outstandingShares":null,"numberOfSubsidiary":2.0,"bps":190.88,"equityRatio":0.941,"cashAndCashEquivalents":2061316000.0,"assets":4251235000.0,"currentAssets":2834232000.0,"fixedAsset":1417002000.0,"tangibleFixedAssets":332967000.0,"intangibleFixedAssets":33005000.0,"investmentAndOtherAssets":1051029000.0,"liabilities":240106000.0,"currentLiabilities":186662000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":53443000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":4011129000.0,"capitalStock":3994407000.0,"capital":2255401000.0,"capitalSurplus":2445184000.0,"accumulatedEarnings":-706157000.0,"treasuryStock":-21000.0,"valuationAndConversionAdjustments":4809000.0,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":null,"costOfSales":null,"grossProfit":null,"sgaExpenses":null,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":-486078000.0,"nonOperatingIncome":34660000.0,"nonOperatingExpenses":76237000.0,"interestExpense":436000.0,"ordinaryProfit":-527654000.0,"extraordinaryGain":9180000.0,"extraordinaryLoss":9466000.0,"incomeBeforeTax":-527941000.0,"incomeTaxes":79044000.0,"netIncome":-606985000.0,"netIncomeAttributableToOwnersOfTheParentCompany":-606985000.0,"comprehensiveIncome":-610082000.0,"eps":-28.97,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":-289208000.0,"depreciationAndCashflowFromOperatingActivities":124255000.0,"cashFlowFromInvestingActivities":225475000.0,"cashFlowFromFinancialActivities":-6961000.0,"changesInCashAndCashEquivalents":-138890000.0,"列1":"asr","submitDate":"2021\/3\/30","stockCode":4579,"accountingYear":"第13期（自　2020年１月１日　至　2020年12月31日）","accountingYearStart":"2020\/1\/1","accountingYearEnd":"2020\/12\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E25269","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":2254,"settlementDate":"2022\/12\/31","submitterName":"ラクオリア創薬株式会社","submitterNameEnglish":"RaQualia Pharma Inc.","submitterNameKana":"ラクオリアソウヤクカブシキカイシャ","location":"名古屋市中村区名駅南一丁目２１番１９号","industory":"医薬品","corporateNumber":3180000000000.0},{"edinetCode":"E25269","endDate":"2021\/3\/31","Report abbreviation_x":"q1r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.909,"cashAndCashEquivalents":2041418000.0,"assets":4628272000.0,"currentAssets":3328551000.0,"fixedAsset":1299720000.0,"tangibleFixedAssets":362107000.0,"intangibleFixedAssets":36383000.0,"investmentAndOtherAssets":901229000.0,"liabilities":410176000.0,"currentLiabilities":357668000.0,"shorTermDept":10000000.0,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":52507000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":4218096000.0,"capitalStock":4182985000.0,"capital":2255401000.0,"capitalSurplus":2445184000.0,"accumulatedEarnings":-517579000.0,"treasuryStock":-21000.0,"valuationAndConversionAdjustments":23198000.0,"Report abbreviation_y":"q1r","context_y":"当四半期累計期間連結期間","Sales":null,"costOfSales":null,"grossProfit":null,"sgaExpenses":null,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":149043000.0,"nonOperatingIncome":121738000.0,"nonOperatingExpenses":2438000.0,"interestExpense":398000.0,"ordinaryProfit":268343000.0,"extraordinaryGain":3382000.0,"extraordinaryLoss":null,"incomeBeforeTax":271726000.0,"incomeTaxes":83148000.0,"netIncome":188578000.0,"netIncomeAttributableToOwnersOfTheParentCompany":188578000.0,"comprehensiveIncome":206967000.0,"eps":9.0,"dilutedEps":9.0,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":52516000.0,"depreciationAndCashflowFromOperatingActivities":32324000.0,"cashFlowFromInvestingActivities":-154771000.0,"cashFlowFromFinancialActivities":6931000.0,"changesInCashAndCashEquivalents":-19898000.0,"列1":"q1r","submitDate":"2021\/5\/14","stockCode":4579,"accountingYear":null,"accountingYearStart":"2021\/1\/1","accountingYearEnd":"2021\/12\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E25269","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":2254,"settlementDate":"2022\/12\/31","submitterName":"ラクオリア創薬株式会社","submitterNameEnglish":"RaQualia Pharma Inc.","submitterNameKana":"ラクオリアソウヤクカブシキカイシャ","location":"名古屋市中村区名駅南一丁目２１番１９号","industory":"医薬品","corporateNumber":3180000000000.0},{"edinetCode":"E25269","endDate":"2021\/6\/30","Report abbreviation_x":"q2r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":6216892.0,"sharesOwendPercent":0.2967,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.908,"cashAndCashEquivalents":2133241000.0,"assets":4768335000.0,"currentAssets":3280930000.0,"fixedAsset":1487404000.0,"tangibleFixedAssets":333197000.0,"intangibleFixedAssets":36812000.0,"investmentAndOtherAssets":1117394000.0,"liabilities":425407000.0,"currentLiabilities":371496000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":53911000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":4342927000.0,"capitalStock":4297235000.0,"capital":2255401000.0,"capitalSurplus":2445184000.0,"accumulatedEarnings":-403329000.0,"treasuryStock":-21000.0,"valuationAndConversionAdjustments":33779000.0,"Report abbreviation_y":"q2r","context_y":"当四半期累計期間連結期間","Sales":null,"costOfSales":null,"grossProfit":null,"sgaExpenses":null,"salaryAndBenefit":77500000.0,"depreciationAndSGA":2629000.0,"RDExpenses":null,"operatingIncome":314976000.0,"nonOperatingIncome":129768000.0,"nonOperatingExpenses":11775000.0,"interestExpense":665000.0,"ordinaryProfit":432969000.0,"extraordinaryGain":3382000.0,"extraordinaryLoss":null,"incomeBeforeTax":436352000.0,"incomeTaxes":133523000.0,"netIncome":302828000.0,"netIncomeAttributableToOwnersOfTheParentCompany":302828000.0,"comprehensiveIncome":331798000.0,"eps":14.45,"dilutedEps":14.45,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":368338000.0,"depreciationAndCashflowFromOperatingActivities":67071000.0,"cashFlowFromInvestingActivities":-372592000.0,"cashFlowFromFinancialActivities":-5953000.0,"changesInCashAndCashEquivalents":71925000.0,"列1":"q2r","submitDate":"2021\/8\/12","stockCode":4579,"accountingYear":null,"accountingYearStart":"2021\/1\/1","accountingYearEnd":"2021\/12\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E25269","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":2254,"settlementDate":"2022\/12\/31","submitterName":"ラクオリア創薬株式会社","submitterNameEnglish":"RaQualia Pharma Inc.","submitterNameKana":"ラクオリアソウヤクカブシキカイシャ","location":"名古屋市中村区名駅南一丁目２１番１９号","industory":"医薬品","corporateNumber":3180000000000.0},{"edinetCode":"E25269","endDate":"2021\/9\/30","Report abbreviation_x":"q3r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.932,"cashAndCashEquivalents":2209778000.0,"assets":4502764000.0,"currentAssets":3137419000.0,"fixedAsset":1365345000.0,"tangibleFixedAssets":321648000.0,"intangibleFixedAssets":35770000.0,"investmentAndOtherAssets":1007926000.0,"liabilities":294229000.0,"currentLiabilities":243994000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":50234000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":4208535000.0,"capitalStock":4166779000.0,"capital":2256920000.0,"capitalSurplus":2446703000.0,"accumulatedEarnings":-536824000.0,"treasuryStock":-21000.0,"valuationAndConversionAdjustments":30906000.0,"Report abbreviation_y":"q3r","context_y":"当四半期累計期間連結期間","Sales":null,"costOfSales":null,"grossProfit":null,"sgaExpenses":null,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":107179000.0,"nonOperatingIncome":153373000.0,"nonOperatingExpenses":22207000.0,"interestExpense":905000.0,"ordinaryProfit":238345000.0,"extraordinaryGain":5650000.0,"extraordinaryLoss":null,"incomeBeforeTax":243996000.0,"incomeTaxes":74662000.0,"netIncome":169333000.0,"netIncomeAttributableToOwnersOfTheParentCompany":169333000.0,"comprehensiveIncome":195430000.0,"eps":8.08,"dilutedEps":8.08,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":561570000.0,"depreciationAndCashflowFromOperatingActivities":103842000.0,"cashFlowFromInvestingActivities":-487032000.0,"cashFlowFromFinancialActivities":-6716000.0,"changesInCashAndCashEquivalents":148462000.0,"列1":"q3r","submitDate":"2021\/11\/12","stockCode":4579,"accountingYear":null,"accountingYearStart":"2021\/1\/1","accountingYearEnd":"2021\/12\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E25269","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":2254,"settlementDate":"2022\/12\/31","submitterName":"ラクオリア創薬株式会社","submitterNameEnglish":"RaQualia Pharma Inc.","submitterNameKana":"ラクオリアソウヤクカブシキカイシャ","location":"名古屋市中村区名駅南一丁目２１番１９号","industory":"医薬品","corporateNumber":3180000000000.0}]